MX350309B - Nanocristales novedosos basados en oro para tratamientos medicos y procedimientos de fabricacion electroquimica para los mismos. - Google Patents
Nanocristales novedosos basados en oro para tratamientos medicos y procedimientos de fabricacion electroquimica para los mismos.Info
- Publication number
- MX350309B MX350309B MX2012000489A MX2012000489A MX350309B MX 350309 B MX350309 B MX 350309B MX 2012000489 A MX2012000489 A MX 2012000489A MX 2012000489 A MX2012000489 A MX 2012000489A MX 350309 B MX350309 B MX 350309B
- Authority
- MX
- Mexico
- Prior art keywords
- gold
- conditions
- nanocrystals
- novel
- manufacturing processes
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N55/00—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur
- A01N55/02—Biocides, pest repellants or attractants, or plant growth regulators, containing organic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen and sulfur containing metal atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
- B22F1/0545—Dispersions or suspensions of nanosized particles
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F1/00—Metallic powder; Treatment of metallic powder, e.g. to facilitate working or to improve properties
- B22F1/05—Metallic powder characterised by the size or surface area of the particles
- B22F1/054—Nanosized particles
- B22F1/0553—Complex form nanoparticles, e.g. prism, pyramid, octahedron
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B22—CASTING; POWDER METALLURGY
- B22F—WORKING METALLIC POWDER; MANUFACTURE OF ARTICLES FROM METALLIC POWDER; MAKING METALLIC POWDER; APPARATUS OR DEVICES SPECIALLY ADAPTED FOR METALLIC POWDER
- B22F9/00—Making metallic powder or suspensions thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
- B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y30/00—Nanotechnology for materials or surface science, e.g. nanocomposites
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B1/00—Single-crystal growth directly from the solid state
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/02—Elements
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B29/00—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape
- C30B29/60—Single crystals or homogeneous polycrystalline material with defined structure characterised by the material or by their shape characterised by shape
-
- C—CHEMISTRY; METALLURGY
- C30—CRYSTAL GROWTH
- C30B—SINGLE-CRYSTAL GROWTH; UNIDIRECTIONAL SOLIDIFICATION OF EUTECTIC MATERIAL OR UNIDIRECTIONAL DEMIXING OF EUTECTOID MATERIAL; REFINING BY ZONE-MELTING OF MATERIAL; PRODUCTION OF A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; SINGLE CRYSTALS OR HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; AFTER-TREATMENT OF SINGLE CRYSTALS OR A HOMOGENEOUS POLYCRYSTALLINE MATERIAL WITH DEFINED STRUCTURE; APPARATUS THEREFOR
- C30B7/00—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions
- C30B7/12—Single-crystal growth from solutions using solvents which are liquid at normal temperature, e.g. aqueous solutions by electrolysis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nanotechnology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Crystallography & Structural Chemistry (AREA)
- Materials Engineering (AREA)
- Metallurgy (AREA)
- Neurology (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Dispersion Chemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Electrochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Condensed Matter Physics & Semiconductors (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
Abstract
La presente invención se refiere a nanocristales novedosos de oro y distribuciones de forma de nanocristal que tienen superficies que son sustancialmente libres de impurezas orgánicas o de otras o películas; específicamente, las superficies son "limpias", en relación a las superficies de nanopartículas de oro realizadas mediante procedimientos de reducción química que requieren reductores orgánico y/o agentes tensoactivos para hacer crecer nanopartículas de oro de iones de oro en la solución; la invención incluye aparatos de fabricación electroquímica y técnicas para la fabricación de los nanocristales basados en oro; la invención además incluye composiciones farmacéuticas de los mismos y el uso de nanocristales de oro o suspensiones o coloides de los mismos para el tratamiento o prevención de enfermedades o condiciones para las que se conoce la terapia de oro y más generalmente para condiciones resultantes de la activación celular patológica, tal como condiciones inflamatorias (incluyendo inflamatoria crónica), condiciones autoinmunes, reacciones de hipersensibilidad y/o enfermedades cancerosas o condiciones, en una modalidad, la condición es mediada por MIF (factor de inhibición de migración de macrófagos).
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22394409P | 2009-07-08 | 2009-07-08 | |
US22615309P | 2009-07-16 | 2009-07-16 | |
US22825009P | 2009-07-24 | 2009-07-24 | |
US23557409P | 2009-08-20 | 2009-08-20 | |
US24980409P | 2009-10-08 | 2009-10-08 | |
US26364809P | 2009-11-23 | 2009-11-23 | |
US29469010P | 2010-01-13 | 2010-01-13 | |
PCT/US2010/041427 WO2011006007A1 (en) | 2009-07-08 | 2010-07-08 | Novel gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2012000489A MX2012000489A (es) | 2012-07-30 |
MX350309B true MX350309B (es) | 2017-09-01 |
Family
ID=43429549
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2012000489A MX350309B (es) | 2009-07-08 | 2010-07-08 | Nanocristales novedosos basados en oro para tratamientos medicos y procedimientos de fabricacion electroquimica para los mismos. |
Country Status (16)
Country | Link |
---|---|
US (5) | US9603870B2 (es) |
EP (1) | EP2451284B8 (es) |
JP (4) | JP6059015B2 (es) |
KR (3) | KR102131575B1 (es) |
CN (1) | CN102548417B (es) |
AU (1) | AU2010271298B2 (es) |
BR (1) | BR112012000311B1 (es) |
CA (1) | CA2767428C (es) |
DK (1) | DK2451284T3 (es) |
ES (1) | ES2623504T3 (es) |
IL (1) | IL217408A (es) |
MX (1) | MX350309B (es) |
PH (1) | PH12017501884A1 (es) |
RU (1) | RU2568850C2 (es) |
SG (4) | SG10202108051XA (es) |
WO (1) | WO2011006007A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2178796T1 (sl) * | 2007-07-11 | 2021-04-30 | Clene Nanomedicine, Inc. | Kontinuiran postopek za obdelavo tekočin in proizvodnjo določenih sestavin |
US9387452B2 (en) | 2009-01-14 | 2016-07-12 | Gr Intellectual Reserve, Llc. | Continuous methods for treating liquids and manufacturing certain constituents (e.g., nanoparticles) in liquids, apparatuses and nanoparticles and nanoparticle/liquid solution(s) resulting therefrom |
EP3427871A1 (en) | 2009-01-15 | 2019-01-16 | Clene Nanomedicine, Inc. | Continuous, semicontinuous and batch methods for treating liquids and manufacturing certain constituents (e.g., nanoparticles) in liquids, apparatuses and nanoparticles and nanoparticle/liquid solution(s) and colloids resulting therefrom |
SG10202108051XA (en) * | 2009-07-08 | 2021-09-29 | Clene Nanomedicine Inc | Novel gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor |
WO2011158176A2 (en) * | 2010-06-17 | 2011-12-22 | University Of Kwazulu-Natal | Gold complexes |
US20130323166A1 (en) * | 2010-09-10 | 2013-12-05 | William Beaumont Hospital | Radiation Therapy for Treating Alzheimer's Disease |
KR102103534B1 (ko) * | 2011-03-30 | 2020-04-23 | 클레네 나노메디슨, 인크. | 신규한 골드-백금계 복금속 나노결정 현탁액, 그의 전기화학 제조 방법 및 그의 용도 |
EP2735389A1 (de) * | 2012-11-23 | 2014-05-28 | Universität Duisburg-Essen | Verfahren zur Herstellung reiner, insbesondere kohlenstofffreier Nanopartikel |
KR20210018955A (ko) * | 2013-05-08 | 2021-02-18 | 종이앤 장 | 특정 탈수초화 및 수초형성부전-기초 장애를 치료하고/하거나 재수초화를 촉진하는 방법 |
GB2529185B (en) | 2014-08-12 | 2021-03-03 | Kathrein Se | Method and system for relaying telecommunications signals wtih efficient joint capacity |
EP3689234A1 (en) | 2014-10-30 | 2020-08-05 | Kardium Inc. | Systems and methods for ablating tissue |
KR102328995B1 (ko) * | 2014-11-26 | 2021-11-23 | 나노리소스 주식회사 | 폭발형 나노다이아몬드의 분리 방법 |
CN104867267B (zh) * | 2015-03-15 | 2017-10-27 | 李洪 | 节能减灾装置 |
CN104759753B (zh) * | 2015-03-30 | 2016-08-31 | 江苏大学 | 多系统自动化协调工作提高激光诱导空化强化的方法 |
WO2016179477A1 (en) * | 2015-05-07 | 2016-11-10 | The Regents Of The University Of Michigan | Process for electro-hydrodynamically enhanced destruction of chemical air contaminants and airborne inactivation of biological agents |
JP6590309B2 (ja) * | 2015-07-31 | 2019-10-16 | 学校法人関東学院 | 導電層付プラスチック基板及びその製造方法 |
US11311940B2 (en) | 2016-05-25 | 2022-04-26 | University Of Florida Research Foundation, Inc. | Light-driven synthesis of plasmonic nanoparticles and nanomaterials |
CN107684560B (zh) * | 2016-08-05 | 2021-05-11 | 深圳深见医药科技有限公司 | 含金团簇的物质在制备预防和治疗阿兹海默病药物中的应用 |
US10195683B2 (en) * | 2016-11-14 | 2019-02-05 | Matthew Fagan | Metal analyzing plasma CNC cutting machine and associated methods |
US10300551B2 (en) | 2016-11-14 | 2019-05-28 | Matthew Fagan | Metal analyzing plasma CNC cutting machine and associated methods |
US10029019B1 (en) | 2017-01-20 | 2018-07-24 | Xueyun Gao | Method for mitigating osteoporosis using metallic gold cluster molecules |
CN108569483A (zh) * | 2017-03-13 | 2018-09-25 | 富泰华工业(深圳)有限公司 | 智能取液系统 |
CN107217279B (zh) * | 2017-05-31 | 2018-10-02 | 东北大学 | 一种电解法制备金属纳米颗粒的方法 |
CN107290422B (zh) * | 2017-07-20 | 2019-04-19 | 浙江大学 | 一种基于电化学增强反射光谱信号的生化检测系统及方法 |
TWI651095B (zh) * | 2017-10-18 | 2019-02-21 | 晶碩光學股份有限公司 | 具有抗敏舒緩效果的眼用產品 |
MX2020006360A (es) | 2017-12-19 | 2020-08-17 | Nanobiotix | Nanoparticulas para su uso para tratar un trastorno neuronal. |
AU2018390163B2 (en) | 2017-12-19 | 2024-05-02 | Nanobiotix | Nanoparticles for use in enhancing brain performances or in treating stress |
EP3696534A1 (en) * | 2019-02-14 | 2020-08-19 | SmartDyeLivery GmbH | Method for determining physicochemical properties of nanoscale systems (nss) |
CN110905454B (zh) * | 2019-11-29 | 2022-01-04 | 南通仁隆科研仪器有限公司 | 一种水合物储层井间电学动态监控模拟实验装置 |
RU2725197C1 (ru) * | 2020-02-12 | 2020-06-30 | федеральное государственное бюджетное образовательное учреждение высшего образования «Ижевская государственная медицинская академия» Министерства здравоохранения Российской Федерации | Метод оценки висцеральной гиперчувствительности |
KR102408166B1 (ko) * | 2020-04-02 | 2022-06-10 | 아주대학교산학협력단 | 세포 배양이 가능한 세포 유래물 분석용 센서칩, 및 이를 이용한 세포 활성도 정량 분석 방법 |
CN112571790A (zh) * | 2020-11-04 | 2021-03-30 | 即时智造科技(上海)有限公司 | 一种sls3d打印自动冷却装置 |
CN112683710B (zh) * | 2020-12-02 | 2024-04-16 | 大连理工大学 | 一种氯离子侵蚀下钢筋混凝土桥板加速腐蚀的试验装置 |
CN115351289B (zh) * | 2022-09-01 | 2023-12-29 | 杭州师范大学 | 一种利用三元表面活性剂制备微型金纳米棒的方法及其产品 |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR432101A (fr) | 1910-10-26 | 1911-11-29 | I S Petzholdt Maschinen Fabrik | Procédé et machine destinés au traitement du cacao fluide |
JPS529615B1 (es) | 1970-03-31 | 1977-03-17 | ||
JPS5747272B2 (es) | 1974-12-13 | 1982-10-08 | ||
DE2854946A1 (de) | 1978-12-20 | 1980-07-10 | Agfa Gevaert Ag | Fotografisches farbdiffusionsuebertragungsverfahren |
US6638413B1 (en) | 1989-10-10 | 2003-10-28 | Lectro Press, Inc. | Methods and apparatus for electrolysis of water |
CA2104355C (en) | 1993-08-18 | 1997-06-17 | Ion I. Inculet | Method and apparatus for ozone generation and treatment of water |
DE19522619C2 (de) | 1995-06-22 | 1998-11-12 | Fischer & Krecke Gmbh & Co | Verfahren zur Herstellung von Bodenbeuteln mit Innenriegel |
US5876663A (en) | 1995-11-14 | 1999-03-02 | The University Of Tennessee Research Corporation | Sterilization of liquids using plasma glow discharge |
ZA9610018B (en) | 1995-11-28 | 1997-05-28 | Austech Pty Ltd | Liquid sterilisation apparatus |
AUPO502297A0 (en) | 1997-02-10 | 1997-03-06 | Austech Pty Ltd | Liquid purification apparatus |
US5965994A (en) | 1997-06-20 | 1999-10-12 | Seo; Dong Il | Automatic vertical moving systems and control methods therefor |
US6558638B2 (en) | 1998-03-14 | 2003-05-06 | Splits Technologies Limited | Treatment of liquids |
US7527787B2 (en) * | 2005-10-19 | 2009-05-05 | Ibc Pharmaceuticals, Inc. | Multivalent immunoglobulin-based bioactive assemblies |
CA2272596A1 (en) | 1999-05-21 | 2000-11-21 | Lawrence A. Lambert | Waste water treatment method and apparatus |
US6214299B1 (en) | 1999-06-01 | 2001-04-10 | Robert J. Holladay | Apparatus and method for producing antimicrobial silver solution |
US7135195B2 (en) | 1999-06-01 | 2006-11-14 | American Silver, Llc | Treatment of humans with colloidal silver composition |
US7238472B2 (en) | 2001-05-25 | 2007-07-03 | Nanosphere, Inc. | Non-alloying core shell nanoparticles |
US6962679B2 (en) | 2001-07-11 | 2005-11-08 | Battelle Memorial Institute | Processes and apparatuses for treating halogen-containing gases |
US7135054B2 (en) | 2001-09-26 | 2006-11-14 | Northwestern University | Nanoprisms and method of making them |
TWI255695B (en) * | 2001-10-12 | 2006-06-01 | Phild Co Ltd | Method and device for producing ultrafine dispersion of noble metal |
TW561085B (en) | 2001-10-29 | 2003-11-11 | Phild Co Ltd | Method and device for producing metal powder |
US7972390B2 (en) | 2002-03-21 | 2011-07-05 | Gr Intellectual Reserve, Llc | Methods for controlling crystal growth, crystallization, structures and phases in materials and systems |
GB0208263D0 (en) | 2002-04-10 | 2002-05-22 | Dow Corning | Protective coating composition |
US7118852B2 (en) | 2002-04-11 | 2006-10-10 | Throwleigh Technologies, L.L.C. | Methods and apparatus for decontaminating fluids |
US6749759B2 (en) | 2002-07-12 | 2004-06-15 | Wisconsin Alumni Research Foundation | Method for disinfecting a dense fluid medium in a dense medium plasma reactor |
US20040022702A1 (en) | 2002-07-30 | 2004-02-05 | Christensen Herbert E. | Apparatus and method for automatically feeding the silver electrode into the solutiion |
JP2004124155A (ja) | 2002-10-01 | 2004-04-22 | Sumitomo Electric Ind Ltd | 微小金属粉末の製造方法および微小金属粉末の製造装置 |
US6802981B2 (en) | 2002-11-05 | 2004-10-12 | Aquapure Technologies Ltd. | Method for purification and disinfection of water |
WO2004073723A1 (ja) * | 2003-02-20 | 2004-09-02 | She Tec Co., Ltd. | 貴金属微粒子を含む医薬 |
AU2004228655A1 (en) | 2003-04-02 | 2004-10-21 | Northwestern University | Methods of controlling nanoparticle growth |
US20060249705A1 (en) | 2003-04-08 | 2006-11-09 | Xingwu Wang | Novel composition |
EP1652206A2 (en) * | 2003-07-28 | 2006-05-03 | The Regents of the University of California, Office of the President | Langmuir-blodgett nanostructure monolayers |
JP2007504944A (ja) | 2003-09-10 | 2007-03-08 | パランスキ ナフム | ナノ粒子及びマイクロ粒子の製造方法 |
US7276283B2 (en) | 2004-03-24 | 2007-10-02 | Wisconsin Alumni Research Foundation | Plasma-enhanced functionalization of carbon-containing substrates |
US7486705B2 (en) | 2004-03-31 | 2009-02-03 | Imra America, Inc. | Femtosecond laser processing system with process parameters, controls and feedback |
US20060068026A1 (en) * | 2004-08-11 | 2006-03-30 | Hu Michael Z | Thermal electrochemical synthesis method for production of stable colloids of "naked" metal nanocrystals |
US8512436B2 (en) | 2004-09-15 | 2013-08-20 | Kyoto University | Metal fine particles and manufacturing method therefor |
WO2006137851A2 (en) | 2004-09-16 | 2006-12-28 | Virginia Tech Intellectual Properties, Inc. | Preparation of stable high concentration colloidal metal particulate systems |
ES2392443T3 (es) * | 2004-10-05 | 2012-12-10 | Inovex Co., Ltd. | Uso de una solución acuosa que contiene coloide de platino para el tratamiento de síntomas psiquiátricos |
WO2006065762A2 (en) * | 2004-12-13 | 2006-06-22 | University Of South Carolina | Surface enhanced raman spectroscopy using shaped gold nanoparticles |
CN101389221B (zh) | 2005-01-05 | 2012-06-13 | 罗伯特·霍拉迪 | 银/水、银凝胶和银基组合物及用于制造和使用该组合物的方法 |
US7588624B2 (en) * | 2005-03-10 | 2009-09-15 | Northwestern University | Method of producing gold nanoprisms |
CN100467118C (zh) | 2005-08-08 | 2009-03-11 | 鸿富锦精密工业(深圳)有限公司 | 纳米粒子制备装置 |
KR100726713B1 (ko) | 2005-08-26 | 2007-06-12 | 한국전기연구원 | 액중 전기폭발에 의한 나노분말 제조 방법 및 장치 |
EP1945577A1 (en) | 2005-10-06 | 2008-07-23 | Pionetics, Inc. | Electrochemical ion exchange treatment of fluids |
US7758846B2 (en) * | 2005-12-16 | 2010-07-20 | Battelle Memorial Institute | Methods of producing hydrogen via the water-gas shift reaction over a Pd-Zn catalyst |
US20070267289A1 (en) | 2006-04-06 | 2007-11-22 | Harry Jabs | Hydrogen production using plasma- based reformation |
US8088193B2 (en) | 2006-12-16 | 2012-01-03 | Taofang Zeng | Method for making nanoparticles |
US7862782B2 (en) | 2007-01-12 | 2011-01-04 | Wisconsin Alumni Research Foundation | Apparatus and methods for producing nanoparticles in a dense fluid medium |
SI2178796T1 (sl) * | 2007-07-11 | 2021-04-30 | Clene Nanomedicine, Inc. | Kontinuiran postopek za obdelavo tekočin in proizvodnjo določenih sestavin |
JP2009032756A (ja) * | 2007-07-25 | 2009-02-12 | Sony Corp | 半導体製造装置 |
CN101952197A (zh) | 2008-01-14 | 2011-01-19 | 曾桃芳 | 一种制造纳米颗粒或微细颗粒的方法 |
EP2123262A1 (en) * | 2008-05-20 | 2009-11-25 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte-encapsulated gold nanoparticles capable of crossing blood-brain barrier |
EP3427871A1 (en) * | 2009-01-15 | 2019-01-16 | Clene Nanomedicine, Inc. | Continuous, semicontinuous and batch methods for treating liquids and manufacturing certain constituents (e.g., nanoparticles) in liquids, apparatuses and nanoparticles and nanoparticle/liquid solution(s) and colloids resulting therefrom |
US8246714B2 (en) | 2009-01-30 | 2012-08-21 | Imra America, Inc. | Production of metal and metal-alloy nanoparticles with high repetition rate ultrafast pulsed laser ablation in liquids |
SG10202108051XA (en) * | 2009-07-08 | 2021-09-29 | Clene Nanomedicine Inc | Novel gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor |
EP2275137A1 (en) | 2009-07-10 | 2011-01-19 | Nanobiotix | Metallic nanoparticles, preparation and uses thereof |
US8858676B2 (en) | 2010-02-10 | 2014-10-14 | Imra America, Inc. | Nanoparticle production in liquid with multiple-pulse ultrafast laser ablation |
US8802234B2 (en) | 2011-01-03 | 2014-08-12 | Imra America, Inc. | Composite nanoparticles and methods for making the same |
-
2010
- 2010-07-08 SG SG10202108051XA patent/SG10202108051XA/en unknown
- 2010-07-08 SG SG2012001319A patent/SG177565A1/en unknown
- 2010-07-08 AU AU2010271298A patent/AU2010271298B2/en active Active
- 2010-07-08 CA CA2767428A patent/CA2767428C/en active Active
- 2010-07-08 RU RU2012104247/15A patent/RU2568850C2/ru active
- 2010-07-08 KR KR1020197034776A patent/KR102131575B1/ko active IP Right Grant
- 2010-07-08 US US13/382,781 patent/US9603870B2/en active Active
- 2010-07-08 KR KR1020187036075A patent/KR102051248B1/ko active IP Right Grant
- 2010-07-08 ES ES10797874.4T patent/ES2623504T3/es active Active
- 2010-07-08 KR KR1020127003346A patent/KR101931381B1/ko active Application Filing
- 2010-07-08 DK DK10797874.4T patent/DK2451284T3/en active
- 2010-07-08 SG SG10201908339R patent/SG10201908339RA/en unknown
- 2010-07-08 BR BR112012000311-9A patent/BR112012000311B1/pt active IP Right Grant
- 2010-07-08 CN CN201080036729.4A patent/CN102548417B/zh active Active
- 2010-07-08 EP EP10797874.4A patent/EP2451284B8/en active Active
- 2010-07-08 SG SG10201403497QA patent/SG10201403497QA/en unknown
- 2010-07-08 MX MX2012000489A patent/MX350309B/es active IP Right Grant
- 2010-07-08 WO PCT/US2010/041427 patent/WO2011006007A1/en active Application Filing
- 2010-07-08 JP JP2012519739A patent/JP6059015B2/ja active Active
-
2012
- 2012-01-05 IL IL217408A patent/IL217408A/en active IP Right Grant
-
2016
- 2016-08-18 JP JP2016160686A patent/JP6383763B2/ja active Active
-
2017
- 2017-03-21 US US15/465,092 patent/US10449217B2/en active Active
- 2017-10-18 PH PH12017501884A patent/PH12017501884A1/en unknown
-
2018
- 2018-08-06 JP JP2018147599A patent/JP6703052B2/ja active Active
-
2019
- 2019-08-08 US US16/535,672 patent/US10980832B2/en active Active
-
2020
- 2020-04-28 JP JP2020079822A patent/JP7014851B2/ja active Active
-
2021
- 2021-04-06 US US17/223,336 patent/US20210236542A1/en active Pending
- 2021-04-13 US US17/229,013 patent/US20210361699A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017501884A1 (en) | Novel gold-based nanocrystals for medical treatments and electrochemical manufacturing processes therefor | |
WO2012135743A3 (en) | Novel gold-platinum based bi-metallic nanocrystal suspensions, electrochemical manufacturing processes therefor and uses for the same | |
IN2012DN03799A (es) | ||
PH12015500849B1 (en) | Microporous zirconium silicate for treating hyperkalemia | |
MX354456B (es) | Silicato de zirconio microporoso para el tratamiento de hipercalemia. | |
MA33044B1 (fr) | Composition pharmaceutique contenant des derives de glucopyranosyl diphenylmethane, sa forme posologique galenique, son procede de preparation et ses utilisations pour une regulation glycemique amelioree chez un patient | |
MX337575B (es) | Compuestos de sulfona y métodos para lafabricación y uso de éstos. | |
MX2007003506A (es) | Terapia de combinacion de cancer que comprende azd2171 e imatinib. | |
UA101155C2 (ru) | Модифицированный полипептид фактора vii (fvii) и его применение | |
EA201200473A1 (ru) | Замещенные (гетероарилметил)тиогидантоины | |
MX2010005186A (es) | Tiazolopiridinas solubilizadas. | |
WO2006035204A3 (en) | Combination comprising zd6474 and an imatinib | |
MX2012000285A (es) | Nanoparticulas metalicas, preparacion y uso de las mismas. | |
EA201270205A1 (ru) | Фармацевтические композиции для лечения рака и других заболеваний и нарушений состояния здоровья | |
MX2016000131A (es) | Nanoparticulas polimericas de docetaxel para el tratamiento de cancer. | |
JP2014518847A5 (es) | ||
PH12016500861A1 (en) | Microporous zirconium silicate for the treatment of hyperkalemia | |
Zhao et al. | Titanium dioxide nanoparticle stimulating pro-inflammatory responses in vitro and in vivo for inhibited cancer metastasis | |
ATE502641T1 (de) | Kombination aus azd2171 und pemetrexed | |
Paul et al. | Nanosized silver (II) pyridoxine complex to cause greater inflammatory response and less cytotoxicity to RAW264. 7 macrophage cells | |
WO2007003933A3 (en) | Combination therapy of cancer with azd2171 and gemcitabine | |
IN2014DN04596A (es) | ||
WO2014043243A3 (en) | Platinum compounds, compositions and methods for the treatment of cancer | |
Kazemian et al. | An Evaluation of the Effect of Graphene Oxide-Gold Nanocomposite on HepG2 Cell Line | |
EA201000360A1 (ru) | Гипоаллергенные варианты главного аллергена из пыльцы betula verrucosa |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
GB | Transfer or rights |
Owner name: CLENE NANOMEDICINE, INC. |
|
FG | Grant or registration |